<DOC>
	<DOC>NCT00978627</DOC>
	<brief_summary>This trial is conducted in Europe, Oceania, and the United States of America (USA). The aim of this clinical trial is to compare NN5401 (insulin degludec/insulin aspart (IDegAsp)) with insulin detemir (IDet) plus insulin aspart in patients with type 1 diabetes (main period) followed by the extension period comparing the long-term safety of NN5401 plus insulin aspart with insulin detemir plus insulin aspart. The main period is registered internally at Novo Nordisk as NN5401-3594 while the extension period is registered as NN5401-3645.</brief_summary>
	<brief_title>Comparison of NN5401 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin, Long-Acting</mesh_term>
	<criteria>FOR THE MAIN TRIAL, NN54013594: Type 1 diabetes mellitus for at least 12 months Ongoing daily treatment with insulin (in a basal bolus regimen, premix insulin regimen, self mix regimen) for at least 12 months HbA1c 7.010.0% (both inclusive) BMI (Body Mass Index) below or equal to 35.0 kg/m^2 FOR THE EXTENSION TRIAL, NN54013645: The subject must have completed the sixmonth treatment period in trial NN54013594 FOR THE MAIN TRIAL, NN54013594: Treatment with other insulin regimens than insulin in a basal bolus regimen/premix insulin regimen/self mix regimen within 3 months Cardiovascular disease within the last 6 months Uncontrolled treated/untreated severe hypertension Pregnancy, breastfeeding, the intention of becoming pregnant or not using adequate contraceptive measures according to local requirements Cancer and medical history of cancer FOR THE EXTENSION TRIAL, NN54013645: Anticipated significant lifestyle changes during the trial Pregnancy, breastfeeding, the intention of becoming pregnant or not using adequate contraceptive measures</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>